



April 1st, 2024
Axcelead, Inc.

Notice of Changes in Representative Director

We hereby announce that our Board of Directors has resolved at a meeting held on March 28, 2024, to make the following changes to our representative directors. This change will be officially decided after approval at the Company's annual general meeting of shareholders scheduled in June and at a subsequent meeting of the Board of Directors.

1. Details of changes in representative directors and positions (scheduled for June 2024)

Name	Current Position	New Position
Nobuhiro Todokoro	—	Representative Director, President & CEO
Yoshinori Ikeura	Representative Director, President & CEO	Board Director, Co-CEO and CTO*

※CTO = Chief Technology Officer

【Reason for the change】

To further strengthen our management structure in accelerating the growth of our company group.

【Brief Biography of the New CEO, Nobuhiro Todokoro】

2023 - Managing Director, Whiz Partners Inc. (Scheduled to retire in conjunction with his appointment as President and CEO of Axcelead)

2022 - Representative Director, Senior Managing Executive Officer, Nitto Denko Corporation

2021 - Director, Senior Managing Executive Officer, Nitto Denko Corporation

2019 - Director, Managing Executive Officer, Nitto Denko Corporation

2017 - Executive Officer, General Manager of Information Functional Materials Business Division, Nitto Denko Corporation

Director, Senior Executive Officer, General Manager of Information Functional Materials Business Division, Nitto Denko Corporation

2015 - Executive Officer, General Manager of Information Functional Materials Division, Information Functional Materials Business Unit, Nitto Denko Corporation

1989 - Nitto Denko Corporation



2. Details of Changes in Executive Officers (effective April 1, 2024)

Name	Current Position	New Position
Kengo Okada	—	Corporate Officer CRO* Business
Nobuhiko Yamada	Board Director and Corporate Officer CRO Business	Board Director

*CRO = Contract Research Organization

【About Axcelead】

Axcelead represents a holding company as healthcare platformer which owns a group of companies which are developing a world-class healthcare platform for drug discovery. Axcelead DDP, Japan's first integrated drug discovery CRO, functions as the core company of the Axcelead group that took over Takeda Pharmaceutical Company Limited's drug discovery platform business in 2017. ARCALIS has become Japan's only one-stop mRNA contract drug development and manufacturing organization (CDMO).

Axcelead also owns A-Digital which develops a drug discovery digital platform to increase drug discovery efficacy by 100 times, and the American company, PassPort Technologies, Inc. in San Diego, California ("PassPort"). PassPort is a company that develops combination products of active pharmaceutical ingredients and medical devices based on next-generation transdermal drug delivery technology. Axcelead will promote the drug discovery ecosystem in Japan and will make various contributions to healthcare broadly and globally.

For more information on Axcelead, please visit the company's website at <https://www.axcelead-hd.com>